Mitsubishi Tanabe Pharma Corporation

90 articles with Mitsubishi Tanabe Pharma Corporation

• Mitsubishi Tanabe Pharma America Celebrates ALS Caregiver & Screenwriter Featured In MDA Kevin Hart Kids Telethon

  10/27/2020

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Aleia Kristene Asbey , aspiring screenwriter and participant in the ALSO US ™  caregiver program for teen

• Mitsubishi Tanabe Pharma America Announces Presentations At Northeast Amyotrophic Lateral Sclerosis 19th Annual Meeting

  9/30/2020

   Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the Northeast Amyotrophic Lateral Sclerosis (NEALS) 19 th Annual Meeting, being held virtually Sept. 30 – Oct. 1, 2020 . The data provide deeper insight into U.S. experience wit

• Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) now Eligible for Coverage through Veterans Affairs Canada and Indigenous Services Canada

  9/21/2020

  - Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA ® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), is now reimbursed by Veterans Affairs Canada (VAC) and Indigenous Services Canada via the Non-Insured Health Benefits (NIHB)

• Mitsubishi Tanabe Pharma America Announces Enrollment Has Resumed For The Global Phase 3 Study Of Oral Edaravone For ALS

  8/24/2020

  Mitsubishi Tanabe Pharma America, Inc. announced that the global Phase 3 study to evaluate the long-term safety and tolerability of an investigational oral suspension formulation of edaravone in patients with amyotrophic lateral sclerosis has resumed screening and enrollment.

• Mitsubishi Tanabe Pharma America Honors Third Anniversary Of RADICAVA® (edaravone) In The U.S. & Company's Support Of ALS Community

  8/6/2020

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced updates related to the company's commitment to the amyotrophic lateral sclerosis (ALS) community, in celebration of the third anniversary of the U.S. availability of RADICAVA ® (edaravone).

• Mitsubishi Tanabe Pharma Canada Announces that Nova Scotia has Added the Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

  7/7/2020

  Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA®, an infusion treatment for amyotrophic lateral sclerosis, is now listed on the Nova Scotia Formulary.

• Mitsubishi Tanabe Pharma Canada Announces that Saskatchewan Has Added the Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Plan Formulary

  6/30/2020

  Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA®, an infusion treatment for amyotrophic lateral sclerosis, is now listed on the Saskatchewan Formulary.

• Phase-3 Clinical Trial of MT-7117 INITIATED IN THE U.S. for Rare DiseaseS, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)

  6/19/2020

   Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) has initiated a Phase-3 clinical trial in the U.S. of the selective melanocortin 1 receptor (MC1R) agonist), MT-7117 (dersimelagon

• Mitsubishi Tanabe Pharma Canada announces that company's treatment for amyotrophic lateral sclerosis (ALS) has been added to the Provincial Drug Plan in New Brunswick

  6/18/2020

  Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® is now listed on the New Brunswick Drug Plan formulary.

• Mitsubishi Tanabe Pharma Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta

  6/1/2020

  Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA ® (edaravone) is now listed on the Alberta Drug Benefit List formulary (special authorization). RADICAVA is an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS), a rapidly progressive, neur

• Mitsubishi Tanabe Pharma Canada Announces that Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) has Been Added to the Provincial Drug Plan in Ontario

  5/28/2020

  Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® is now listed on the Ontario Drug Benefit Formulary.

• Mitsubishi Tanabe Pharma America Announces Launch Of The JourneyMate Program, Offering Live Nurse Educational Phone Support For ALS Patients And Caregivers

  5/20/2020

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the launch of RADICAVA ® (edaravone) JourneyMate ™ , a new program connecting people with amyotrophic lateral sclerosis (ALS) and their families to live nurse educational support, which can help answer questions about the disease and treatment options.

• Mitsubishi Tanabe Pharma America Marks Third Anniversary Of FDA Approval And Reports More Than 5,000 Patients With ALS Treated With RADICAVA® (edaravone)

  5/5/2020

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) today reported that more than 5,000 people with amyotrophic lateral sclerosis (ALS) have received the treatment with RADICAVA ® (edaravone) in North America since the therapy was approved by the U.S. Food and Drug Administration (FDA) on May 5, 2017 .  

• Mitsubishi Tanabe Pharma Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec

  4/29/2020

  Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA ® (edaravone) is now listed on the Régie de l'assurance maladie du Québec (RAMQ) formulary (special authorization). RADICAVA is an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS), a ra

• Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (Edaravone)

  4/22/2020

  Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that it has entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance regarding RADICAVA®, an intravenous infusion treatment for amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

• New Post-hoc Analysis of Phase 3 Study Examines Edaravone in ALS Patients with Bulbar and Limb Onset

  3/24/2020

  Data Presented at 2020 Muscular Dystrophy Association Annual Clinical & Scientific Conference

• HitGen and MTPC Enter Into License Agreement

  12/18/2019

  HitGen Inc. announced that HitGen and Mitsubishi Tanabe Pharma Corporation have entered into a license agreement to develop a novel class of drugs.

• Soleo Health Provides Mitsubishi Tanabe Pharma America With Real-World Data for ALS Patients

  12/5/2019

  Soleo Health’s SoleMetrics® Outcomes Program Delivers Real-World Evidence to Pharmaceutical Manufacturers

• Mitsubishi Tanabe Pharma America to Present Real-World Data on RADICAVA® (edaravone) for ALS at the 30th International Symposium on ALS/MND

  12/4/2019

  To obtain real-world data on the use of RADICAVA, MTPA engaged Soleo Health, a provider of home and alternative-site infusions and specialty pharmacy services in the U.S., to share information from 163 patients receiving RADICAVA for at least three months

• Mitsubishi Tanabe Pharma America to Receive Essey Commitment to Cures Award From the ALS Community for Extensive Efforts and Collaboration in ALS Research, Development and Education

  11/15/2019

  ALS Association Golden West Chapter Honors MTPA as a Champion in the Search for ALS Treatments